April 3, 2020

RE: Briviact Prior Authorization Criteria Update

Dear SoonerCare provider,

Effective April 1, 2020, the criteria for Briviact® has changed. Briviact oral tablets and solution now require a failure of one generic anticonvulsant prior to a member being approved. Full criteria listed below.

Briviact® (brivaracetam) Approval Criteria:
1. An FDA approved diagnosis of partial-onset seizures; and
2. Initial prescription must be prescribed by, or in consultation with, a neurologist; and
3. Member must have failed therapy with at least 1 other anticonvulsant; and
4. Members currently stable on Briviact® and who have a seizure diagnosis will be grandfathered; and
5. For Briviact® oral solution, an age restriction of 12 years and younger will apply. Members older than 12 years of age will require a patient-specific, clinically significant reason why the member cannot take the oral tablet formulation; and
6. Approval length for Briviact® intravenous (IV) will be for a maximum of 7 days of therapy. Further approval may be granted if prescriber documents an ongoing need for Briviact® IV therapy over Briviact® oral formulations.

Thank you for the services you provide to Oklahomans insured by SoonerCare!